Who is eligible for clinical trial NCT05322213?

Participants must meet the protocol's inclusion criteria for Type 2 Diabetes. The stated age range is 21 Years to 70 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT05322213 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-06-11

THC Effects on Glucose in Type 2 Diabetes (NCT05322213)

The Effects of THC on Glucose Metabolism and Endothelial Function in Subjects With Type 2 Diabetes

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: University of California, San Diego

🩺 Plain-English Summary (8th-Grade Level)

This study will examine the effects THC has on Glucose Metabolism and Endothelial Functioning in participants with Type 2 Diabetes. The participants will complete blood tests and tests to measure energy expenditure, CVD risks, and glucose metabolism. These tests will be performed prior to start of treatment and again after 2-weeks of treatment with the THC or placebo.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (14 items).

Location: UC San Diego Altman Clinical & Translational Research Institute — La Jolla, California

Age range: 21 Years to 70 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Males and Females 21-70 years old at the time of screening.
Females of non-child bearing potential must be ≥ 1 year post-menopausal or documented as being surgically sterile. Females of child bearing potential must agree to use two methods of contraception during the entire study.
Male subjects must be willing to use clinically acceptable method of contraception during the entire study.
Have a clinical diagnosis of Type 2 Diabetes on a stable medication regimen for at least 3 months.
BMI \> 25 kg/m2).
HbA1c \< 10%).
Negative urine toxicology result at screening visit.
Able to provide written informed consent approved by an Institutional Review Board (IRB).

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
History or presence of any clinically significant illness, as detected by history, physical examination, and/or laboratory tests, that might put the participant at increased risk of adverse events (e.g., history of psychotic disorder, clinically significant mood and/or anxiety disorder, liver, or renal disease).
No prior history of myocardial infarction, stroke or heart failure.
Whole blood donation of 1 pint (500 mL) within 8 weeks prior to Screening. Donations of plasma, packed RBCs, platelets or quantities less than 500 mL are allowed at investigator discretion.
Hemoglobin \< 9g/dL.
Liver enzymes ≥ 2 times upper normal limit and/or clinical signs/symptoms consistent with liver disease, including but not limited to nausea, vomiting, jaundice, itching, abdominal pain, or edema.
History of clinically significant adverse events associated with cannabis intoxication (e.g., severe anxiety and panic, paranoia and psychosis, sustained tachycardia, or severe hypotension).
History of seizures, head trauma, or other history of CNS insult that could predispose the participant to seizures.
Use of any THC containing products within 30 days prior to the screening visit.
Current use of tobacco products.
Individuals who are pregnant or lactating/breastfeeding.
Current use of insulin to treat Type 2 Diabetes.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

UC San Diego Altman Clinical & Translational Research Institute — La Jolla, California

📞 Contact the Study Coordinator

Phone: (858) 246-2169

Email: tmay@health.ucsd.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Type 2 Diabetes

Effects of Different Fish Oil Types on Type 2 Diabetes Risk Factors in High-Risk Adults — Montreal, Quebec
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes — Denver, Colorado
Joint Patient and Caregiver Intervention for Older African Americans With Type 2 Diabetes — Milwaukee, Wisconsin
Validation of an Integrated Attention Model for Patients With Type 2 Diabetes — Mexico City, Mexico City
Continuous Glucose Monitoring System Feasibility in Youth With T2D — San Francisco, California
Polypill for Prevention of Cardiomyopathy — Dallas, Texas

Explore by condition: All Type 2 Diabetes clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗